Biotech Basics: Interpreting Data Readouts
Education - In the last Biotech Basics notes, we covered how to spot incoming financings (read here) and how dilutive instruments can manipulate valuations (read here). This … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Sentiment Check – Bio M&A Is Picking Up
Research - Last week we wrote how the growth in venture capital funds for Q1 2023 was an early sign that private money in biotech was being … Continue Reading
Premium
Biotech Basics: Misunderstood Details of Financings
Education - Biotechnology companies often need to raise capital to fund research and development of their pipeline. In a prior note (read here), we outlined what metrics … Continue Reading
Read now
Biotech Basics: How to Spot When Financing Is Coming
Education - Bio investing is driven by near-term catalysts, rather than a buy & hold strategy. There is a 7.9% likelihood of FDA approval from Phase 1, … Continue Reading
Read now
ADCs Back in Cancer Spotlight
Research - In mid-March 2023, Pfizer acquired Seagen (SGEN) for $43B, making it the largest biopharma transaction in three years. Seagen, considered the leader in antibody-drug conjugate … Continue Reading
Read now
A Very Early Indicator That Bio Markets Could Be Nearing Inflection
Insights - There are early signs that private money in biotech is being accumulated but sitting on the sidelines waiting to be deployed. Q1 2023 was the … Continue Reading
Read now
Day One (DAWN) Sliding On Concerns of Competitoin and Trial Changes
Insights - In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDAapproval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the most … Continue Reading
Premium